Yulia Slavina

KRAS-mutated LGSOC campaign debuts as Verastem, Inc. targets patient support

KRAS-mutated LGSOC campaign debuts as Verastem, Inc. targets patient support
Verastem, Inc. launches LGSOC campaign

Verastem, Inc. has announced the launch of the Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign to raise awareness around the first and only FDA-approved treatment specifically for KRAS-mutated recurrent LGSOC.

The initiative aims to help healthcare professionals rethink support strategies for patients and address the unique challenges faced by this patient community. According to the company, this campaign seeks to improve patient outcomes by encouraging broader engagement and education among healthcare providers.

Verastem previously scheduled its first quarter earnings call for May 7 at 4:30pm ET, set to provide financial results and corporate updates (link). The company has continued to focus on targeted therapies and patient engagement throughout 2024. The latest campaign aligns with ongoing efforts to address unmet medical needs in oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.